CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
View All Press
